Additional Clinical programs
Additional Clinical programs Gibson Oncology has licensed three drugs, invented by the NIH and Purdue University which are now in clinical trials. LMP744, LMP400, LMP776. In addition, Gibson has invented a class of Aza Indenoisoquinolines suitable for oral administration. Mechanisms of Action (1) Non-camptothecin Topoisomerase (Top1) activity. cMYC activity via G-Quadruplex. Mechanisms of Action (2) […]
Overview | LMP744
Lead Program Glioblastoma New treatments are needed in recurrent GBM since median survival with surgery, radiation, and temozolamide (TMZ) is only 14-20 months. LMP744 is a novel non-camptothecin Top-1 and cMYC agent which has been extensively studied by the NCI in pre-clinical and phase I studies in solid tumors and lymphomas. When Gibson Oncology discovered […]
